ALLBRO'S PHARMACY LTD 07132172 false 2024-08-01 2025-07-31 2025-07-31 The principal activity of the company is pharmacy Digita Accounts Production Advanced 6.30.9574.0 true 07132172 2024-08-01 2025-07-31 07132172 2025-07-31 07132172 bus:OrdinaryShareClass1 2025-07-31 07132172 core:RetainedEarningsAccumulatedLosses 2025-07-31 07132172 core:ShareCapital 2025-07-31 07132172 core:CurrentFinancialInstruments 2025-07-31 07132172 core:CurrentFinancialInstruments core:WithinOneYear 2025-07-31 07132172 core:Non-currentFinancialInstruments 2025-07-31 07132172 core:Non-currentFinancialInstruments core:AfterOneYear 2025-07-31 07132172 core:FurnitureFittingsToolsEquipment 2025-07-31 07132172 core:LandBuildings 2025-07-31 07132172 core:MotorVehicles 2025-07-31 07132172 core:OtherPropertyPlantEquipment 2025-07-31 07132172 bus:SmallEntities 2024-08-01 2025-07-31 07132172 bus:AuditExemptWithAccountantsReport 2024-08-01 2025-07-31 07132172 bus:FullAccounts 2024-08-01 2025-07-31 07132172 bus:SmallCompaniesRegimeForAccounts 2024-08-01 2025-07-31 07132172 bus:RegisteredOffice 2024-08-01 2025-07-31 07132172 bus:Director1 2024-08-01 2025-07-31 07132172 bus:Director2 2024-08-01 2025-07-31 07132172 bus:OrdinaryShareClass1 2024-08-01 2025-07-31 07132172 bus:PrivateLimitedCompanyLtd 2024-08-01 2025-07-31 07132172 bus:Agent1 2024-08-01 2025-07-31 07132172 core:RetainedEarningsAccumulatedLosses 2024-08-01 2025-07-31 07132172 core:ShareCapital 2024-08-01 2025-07-31 07132172 core:FurnitureFittingsToolsEquipment 2024-08-01 2025-07-31 07132172 core:LandBuildings 2024-08-01 2025-07-31 07132172 core:MotorVehicles 2024-08-01 2025-07-31 07132172 core:OtherPropertyPlantEquipment 2024-08-01 2025-07-31 07132172 countries:England 2024-08-01 2025-07-31 07132172 dpl:AdministrativeExpenses 2024-08-01 2025-07-31 07132172 dpl:CostSales 2024-08-01 2025-07-31 07132172 2024-07-31 07132172 core:RetainedEarningsAccumulatedLosses 2024-07-31 07132172 core:ShareCapital 2024-07-31 07132172 core:FurnitureFittingsToolsEquipment 2024-07-31 07132172 core:LandBuildings 2024-07-31 07132172 core:MotorVehicles 2024-07-31 07132172 core:OtherPropertyPlantEquipment 2024-07-31 07132172 2023-08-01 2024-07-31 07132172 2024-07-31 07132172 bus:OrdinaryShareClass1 2024-07-31 07132172 core:CurrentFinancialInstruments 2024-07-31 07132172 core:CurrentFinancialInstruments core:WithinOneYear 2024-07-31 07132172 core:Non-currentFinancialInstruments 2024-07-31 07132172 core:Non-currentFinancialInstruments core:AfterOneYear 2024-07-31 07132172 core:FurnitureFittingsToolsEquipment 2024-07-31 07132172 core:LandBuildings 2024-07-31 07132172 core:MotorVehicles 2024-07-31 07132172 core:OtherPropertyPlantEquipment 2024-07-31 07132172 core:RetainedEarningsAccumulatedLosses 2023-08-01 2024-07-31 07132172 core:ShareCapital 2023-08-01 2024-07-31 07132172 dpl:AdministrativeExpenses 2023-08-01 2024-07-31 07132172 dpl:CostSales 2023-08-01 2024-07-31 07132172 2023-07-31 07132172 core:RetainedEarningsAccumulatedLosses 2023-07-31 07132172 core:ShareCapital 2023-07-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 07132172

ALLBRO'S PHARMACY LTD

Annual Report and Unaudited Financial Statements

for the Year Ended 31 July 2025

 

ALLBRO'S PHARMACY LTD

Contents

Company Information

1

Directors' Report

2

Accountants' Report

3

Profit and Loss Account

4

Statement of Comprehensive Income

5

Balance Sheet

6

Statement of Changes in Equity

7

Notes to the Unaudited Financial Statements

8 to 15

iXBRL Detailed Profit and Loss Account

16 to 17

 

ALLBRO'S PHARMACY LTD

Company Information

Directors

Mr Mukaram Sheikh

Mrs Tabassum Sheikh

Registered office

56 Parksway
Manchester
M25 0JB

Accountants

Riaz Ahmad & Co Limited
Chartered Certified AccountantsLord House
51 Lord Street
Manchester
M3 1HE

 

ALLBRO'S PHARMACY LTD

Directors' Report for the Year Ended 31 July 2025

The directors present their report and the financial statements for the year ended 31 July 2025.

Directors of the company

The directors who held office during the year were as follows:

Mr Mukaram Sheikh

Mrs Tabassum Sheikh

Principal activity

The principal activity of the company is pharmacy

Small companies provision statement

This report has been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

Approved and authorised by the Board on 29 July 2026 and signed on its behalf by:
 

.........................................
Mr Mukaram Sheikh
Director

 

Chartered Certified Accountants' Report to the Board of Directors on the Preparation of the Unaudited Statutory Accounts of
ALLBRO'S PHARMACY LTD
for the Year Ended 31 July 2025

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of ALLBRO'S PHARMACY LTD for the year ended 31 July 2025 as set out on pages 4 to 15 from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Association of Chartered Certified Accountants, we are subject to its ethical and other professional requirements which are detailed at https://www.accaglobal.com/gb/en/member/standards/rules-and-standards/rulebook.html.

This report is made solely to the Board of Directors of ALLBRO'S PHARMACY LTD, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the accounts of ALLBRO'S PHARMACY LTD and state those matters that we have agreed to state to the Board of Directors of ALLBRO'S PHARMACY LTD, as a body, in this report in accordance with the requirements of the Association of Chartered Certified Accountants as detailed at http://www.accaglobal.com/gb/en/technical-activities/technical-resources-search/2009/
october/factsheet-163-audit-exempt-companies.html. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than ALLBRO'S PHARMACY LTD and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that ALLBRO'S PHARMACY LTD has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of ALLBRO'S PHARMACY LTD. You consider that ALLBRO'S PHARMACY LTD is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the accounts of ALLBRO'S PHARMACY LTD. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.

......................................

Riaz Ahmad & Co Limited
Chartered Certified Accountants
Lord House
51 Lord Street
Manchester
M3 1HE

29 July 2026

 

ALLBRO'S PHARMACY LTD

Profit and Loss Account for the Year Ended 31 July 2025

Note

2025
£

2024
£

Turnover

 

1,775,328

1,712,121

Cost of sales

 

(1,356,748)

(1,287,741)

Gross profit

 

418,580

424,380

Administrative expenses

 

(273,253)

(239,994)

Operating profit

 

145,327

184,386

Other interest receivable and similar income

 

3,552

2,312

Interest payable and similar expenses

 

(6,117)

(4,908)

   

(2,565)

(2,596)

Profit before tax

4

142,762

181,790

Tax on profit

 

(44,960)

(56,406)

Profit for the financial year

 

97,802

125,384

The above results were derived from continuing operations.

The company has no recognised gains or losses for the year other than the results above.

 

ALLBRO'S PHARMACY LTD

Statement of Comprehensive Income for the Year Ended 31 July 2025

2025
£

2024
£

Profit for the year

97,802

125,384

Total comprehensive income for the year

97,802

125,384

 

ALLBRO'S PHARMACY LTD

(Registration number: 07132172)
Balance Sheet as at 31 July 2025

Note

2025
£

2024
£

Fixed assets

 

Tangible assets

5

157,144

198,196

Current assets

 

Stocks

6

56,300

54,750

Debtors

7

619,692

560,781

Cash at bank and in hand

 

237,131

299,836

 

913,123

915,367

Creditors: Amounts falling due within one year

8

(358,748)

(336,435)

Net current assets

 

554,375

578,932

Total assets less current liabilities

 

711,519

777,128

Creditors: Amounts falling due after more than one year

8

(25,368)

(58,779)

Provisions for liabilities

(60,852)

(60,852)

Net assets

 

625,299

657,497

Capital and reserves

 

Called up share capital

9

3

3

Retained earnings

625,296

657,494

Shareholders' funds

 

625,299

657,497

For the financial year ending 31 July 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and FRS 102 ‘The Financial Reporting Standard Applicable in the UK and Republic of Ireland’.

Approved and authorised by the Board on 29 July 2026 and signed on its behalf by:
 

.........................................
Mr Mukaram Sheikh
Director

 

ALLBRO'S PHARMACY LTD

Statement of Changes in Equity for the Year Ended 31 July 2025

Share capital
£

Retained earnings
£

Total
£

At 1 August 2024

3

657,494

657,497

Profit for the year

-

97,802

97,802

Dividends

-

(130,000)

(130,000)

At 31 July 2025

3

625,296

625,299

Share capital
£

Retained earnings
£

Total
£

At 1 August 2023

3

532,110

532,113

Profit for the year

-

125,384

125,384

At 31 July 2024

3

657,494

657,497

 

ALLBRO'S PHARMACY LTD

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025

1

General information

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
56 Parksway
Manchester
M25 0JB

These financial statements were authorised for issue by the Board on 29 July 2026.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

 

ALLBRO'S PHARMACY LTD

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

 

ALLBRO'S PHARMACY LTD

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 0 (2024 - 0).

4

Profit before tax

Arrived at after charging/(crediting)

2025
£

2024
£

Depreciation expense

45,951

45,214

 

ALLBRO'S PHARMACY LTD

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025

5

Tangible assets

Land and buildings
£

Furniture, fittings and equipment
 £

Motor vehicles
 £

Other tangible assets
£

Total
£

Cost or valuation

At 1 August 2024

91,003

19,376

22,830

307,770

440,979

Additions

-

-

4,900

-

4,900

At 31 July 2025

91,003

19,376

27,730

307,770

445,879

Depreciation

At 1 August 2024

37,190

18,371

17,660

169,562

242,783

Charge for the year

9,068

1,947

4,160

30,777

45,952

At 31 July 2025

46,258

20,318

21,820

200,339

288,735

Carrying amount

At 31 July 2025

44,745

(942)

5,910

107,431

157,144

At 31 July 2024

53,813

1,005

5,170

138,208

198,196

Included within the net book value of land and buildings above is £44,744 (2024 - £53,812) in respect of long leasehold land and buildings.
 

 

ALLBRO'S PHARMACY LTD

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025

6

Stocks

2025
£

2024
£

Other inventories

56,300

54,750

7

Debtors

Current

Note

2025
£

2024
£

Trade debtors

 

274,766

274,402

Amounts owed by related parties

12

187,779

106,389

Prepayments

 

-

2,510

Other debtors

 

157,147

177,480

   

619,692

560,781

 

ALLBRO'S PHARMACY LTD

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025

8

Creditors

Creditors: amounts falling due within one year

Note

2025
£

2024
£

Due within one year

 

Loans and borrowings

10

-

606

Trade creditors

 

244,249

254,222

Taxation and social security

 

113,000

68,461

Accruals and deferred income

 

750

4,500

Other creditors

 

749

8,646

 

358,748

336,435

Creditors: amounts falling due after more than one year

Note

2025
£

2024
£

Due after one year

 

Loans and borrowings

10

25,368

58,779

9

Share capital

Allotted, called up and fully paid shares

2025

2024

No.

£

No.

£

Ordinary Shares at £1 of £1 each

3

3

3

3

       

10

Loans and borrowings

Non-current loans and borrowings

2025
£

2024
£

Bank borrowings

11,392

(658)

Other borrowings

13,976

59,437

25,368

58,779

Current loans and borrowings

2025
£

2024
£

Bank overdrafts

-

606

 

ALLBRO'S PHARMACY LTD

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025

11

Dividends

2025

2024

£

£

 

 

12

Related party transactions

 

ALLBRO'S PHARMACY LTD

Notes to the Unaudited Financial Statements for the Year Ended 31 July 2025

Directors' remuneration

The directors' remuneration for the year was as follows:

2025
£

2024
£

Remuneration

8,320

19,887

 

ALLBRO'S PHARMACY LTD

iXBRL Detailed Profit and Loss Account for the Year Ended 31 July 2025

2025
£

2024
£

Turnover/revenue

1,775,328

1,712,121

Cost of sales

Opening merchandise

(54,750)

(58,500)

Purchase of raw materials and consumables

(1,357,043)

(1,282,563)

Closing merchandise

56,300

54,750

Freight and haulage costs

(1,255)

(1,428)

Gross profit

418,580

424,380

Distribution costs

Administrative expenses

Audit and accountancy other services

(5,167)

(9,118)

Advertising, promotions and marketing costs

(862)

(418)

Rent, rates and services costs

-

(8,133)

Utilities costs

(6,799)

(9,115)

Operating lease expenditure

(19,235)

(3,786)

Other repairs and maintenance costs

(24,970)

(2,890)

Depreciation of fixed assets

(45,951)

(45,214)

Vehicle costs

(17,895)

(14,366)

Wages and salaries excluding directors

(85,452)

(75,549)

Pension costs defined contribution schemes excluding directors

(1,054)

(459)

Staff costs excluding directors

(86,506)

(76,008)

Salaries and fees, directors

(8,320)

(19,887)

Travel and subsistence

(785)

(921)

Legal and professional costs

(3,334)

-

Insurance costs

(16,669)

(14,078)

IT and computing

(22,056)

(18,705)

Telecommunications

(8,702)

(9,563)

Printing, postage and stationery

(1,846)

(999)

Subscriptions

(3,782)

(2,558)

Other costs

(374)

(4,235)

Other operating income

Other items

Profit on ordinary activities before finance charges and interest

145,327

184,386

Bank interest and similar income receivable

3,552

2,312

Interest expense on bank overdraft, bank loans and similar borrowings

(1,624)

(415)

Interest expense on obligations under finance leases and hire purchase contracts

(4,493)

(4,493)

Profit on ordinary activities before taxation

142,762

181,790

 

ALLBRO'S PHARMACY LTD

iXBRL Detailed Profit and Loss Account for the Year Ended 31 July 2025

2025
£

2024
£

Tax on profit or loss on ordinary activities

(44,960)

(56,406)

Profit for the financial year

97,802

125,384